ADVERTISEMENT

Can Immunotherapy Conquer Triple-Negative Breast Cancer?

Triple-negative breast cancer (TNBC) is a subtype of breast cancer, the most common cancer in women. TNBC is clinically negative for expression of the estrogen receptor (ER) and progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2). This disease is highly aggressive and lacks effective targeted therapies. Currently, chemotherapy is the only therapeutic option in the adjuvant or metastatic setting for TNBC.

Although numerous targeted therapies for TNBC have been investigated, the clinical trial efficacies of these therapies are unsatisfactory or remain unclear. Recently, cancer immunotherapy has achieved successes in treating a variety of cancers including refractory malignancies such as metastatic melanoma, advanced lung cancer, and Hodgkin’s lymphoma. Thus, immunotherapy for TNBC is being considered as a viable clinical objective, especially considering the very limited therapeutic options currently available for TNBC.

ADVERTISEMENT

One of the most exciting advances in cancer immunotherapy is the blockade of immune checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA4), programmed cell death protein 1 (PD1), and programmed cell death 1 ligand (PD-L1). Another notable advance in cancer immunotherapy is the chimeric antigen receptor (CAR) T cell therapy. This method has been successfully used to treat refractory leukemia and lymphoma. However, currently, these immunotherapeutic strategies only show beneficial effects in less than 20% of cancer patients. Hence, it is important to find molecular biomarkers that are useful for predicting responders to cancer immunotherapy. Researchers have discovered some such biomarkers, such as tumor mutation burden, neoantigen load, PD-L1 expression, and deficient DNA mismatch repair.

It should be noted that with the rapid advancement of the next-generation sequencing (NGS) technology, it is possible to discover the genomic features that are associated with the cancer immunotherapeutic responsiveness. For example, researchers have found that the tumor mutation load has a positive correlation with clinical response of cancer patients to CTLA4 or PD1 blockade. The high DNA mismatch repair deficiency correlates with active clinical response to cancer immunotherapy.

Immunotherapy has not been clinically used for breast cancer because compared to melanoma, lung cancer, renal cancer, lymphoma, bladder cancer, or head and neck cancer, breast cancer, in general, has weaker immunogenicity. However, researchers showed the existence of distinct immunogenic activity in breast cancer subtypes. Based on a couple of large-scale breast cancer genomics data, researchers performed a comprehensive and exhaustive analysis of various immunogenic signatures in breast cancer.

Strikingly, they found that all the immunogenic signatures showed a significantly stronger signal in TNBC compared to non-TNBC, demonstrating that TNBC has the strongest tumor immunity of all breast cancer subtypes. Particularly, the gene or genomic features such as PD-L1 expression, tumor mutation burden, and neoantigen load that are active signatures for cancer immunotherapeutic response, show significantly higher levels in TNBC than in non-TNBC, indicating that TNBC is the breast cancer subtype most propitious to immunotherapy.

ADVERTISEMENT

Another interesting finding is that most of the immunogenic signatures have a positive correlation with survival prognosis in TNBC. Finally, researchers showed that TNBC had significantly higher expression levels of most of the genes targeted by immunotherapy agents in clinical use or trials or in preclinical development than non-TNBC, indicating that these agents may be good candidates for clinical trials for TNBC immunotherapy.

In conclusion, these findings suggest that of the various breast cancer subtypes, TNBC likely exhibits the strongest immunogenicity, and warrant immunotherapeutic options for TNBC.

These findings are described in the article entitled A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer, recently published in the journal Translational Oncology. This work was conducted by Zhixian Liu, Mengyuan Li, Zehang Jiang and Xiaosheng Wang from China Pharmaceutical University.

Comments (2)

Comments

READ THIS NEXT

Far Ultraviolet Light And Organic Aerosols In Titan And Early Earth Atmospheres

Titan, the largest satellite of Saturn’s system, is famous for being entirely covered by layers of thick orange haze, which […]

Banana Spider: Facts And Photos

“Banana spider” is a colloquial name for spiders in the genus¬†Nephila,¬†also known by the common name¬†golden silk orb-weavers. Spiders in […]

How Accurate Is The Fallout Series Portrayal Of Nuclear Bombs?

With the exciting new announcement of the video game Fallout 76 from Bethesda, we wanted to take a look into […]

Earth Timeline: From 4.5 Billion Years Ago To Today

Over 4.5 billion years ago, our solar system formed from a giant molecular cloud that collapsed under its own tremendous […]

How Are Mountains Formed?

Mountains are some of the most impressive natural structures on earth. Yet how are these massive ridges in the Earth’s […]

Hazardous Alcohol Use Among Patients With Schizophrenia And Depression

Hazardous alcohol use is a pattern of alcohol consumption that places the individual at an increased risk for adverse health […]

Chemical-Biology Space Exploration… To Go Where No Drug Has Gone Before!

The introduction of The Hitch Hiker’s Guide to the Galaxy begins like this: ‚ÄúSpace,‚ÄĚ it says, ‚Äúis big. Really big. […]

Science Trends is a popular source of science news and education around the world. We cover everything from solar power cell technology to climate change to cancer research. We help hundreds of thousands of people every month learn about the world we live in and the latest scientific breakthroughs. Want to know more?